Aortic valve disease can be fatal if left untreated. While many strides have been made in treating this condition with traditional open-heart surgery, there may be other treatment options in the future.
Loyola is one of 40 medical centers across the U.S. to be selected for the CoreValve trial. In this study, participants will undergo an alternative procedure in which an artificial valve is deployed with a catheter.
Cardiac surgeon Mamdouh Bakhos, MD, and interventional cardiologist Fred Leya, MD, explain the benefits of the procedure. If the procedure is successful and receives FDA approval, Dr. Leya says, it would be "one of the greatest advancements" in treating patients with critically blocked aortic valves.
For an appointment or more information, please call (888) LUHS-888, (888-584-7888).